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Critical illness polyneuropathy and myopathy are multifaceted complications that follow severe illnesses involving
the sensorimotor axons and proximal skeletal muscles. These syndromes have rarely been reported among renal
transplant recipients. In this paper, we report a case of acute quadriplegia caused by necrotizing myopathy in a
renal transplant recipient with severe pneumonia. The muscle strength in the patient’s extremities improved
gradually after four weeks of comprehensive treatment, and his daily life activities were normal a year after being
discharged.Background
Critical illness polyneuropathy and myopathy (CIP/CIM)
are complex syndromes caused by various pathophysio-
logical mechanisms in critically ill patients. Muscle weak-
ness and functional impairment can be self-limited for
weeks to months. However, in certain severe cases, these
symptoms can last up to five years after the patient is
discharged [1,2]. No therapies have been proven effective.
The majority of CIP/CIM cases have been reported in pa-
tients with multi-organ dysfunction and sepsis, and these
syndromes have rarely been reported in renal transplant
recipients [3]. In this paper, we present a case of extensive
necrotizing myopathy with favorable recovery in a renal
transplant recipient with severe pneumonia.Case presentation
Our patient was a 60-year-old man with a history of
living-related renal transplantation and subsequent im-
munosuppression therapy (tacrolimus (6 mg/d) plus my-
cophenolate mofetil (2 g/d) plus prednisolone (10 mg/d))* Correspondence: dong.jihong@zs-hospital.sh.cn; luo.zhe@zs-hospital.sh.cn
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unit (ICU) with a five-day history of fever and hypoxia. Bi-
lateral pulmonary inflammatory infiltration was observed
via a chest computed tomography scan. The patient was
empirically treated with moxifloxacin, ganciclovir and
trimethoprim-sulfamethoxazole as anti-infective therapy.
Caspofungin was later administered because a fungal in-
fection was suspected. Finally, the presence of serum cyto-
megalovirus (CMV)-immunoglobulin M and CMV-DNA
suggested a diagnosis of CMV pneumonia.
Along with antibiotics, we gave our patient methylpred-
nisolone (60 mg) every 12 h to reduce the pulmonary in-
flammatory infiltration, and all immunosuppressants were
discontinued [4]. He initially received non-invasive positive-
pressure ventilation therapy. However, after 19 days, se-
vere hypoxemia resulted in him undergoing endotracheal
intubation and mechanical ventilation. Rapid sequence in-
duction was performed using propofol (100 mg), fentanyl
(0.05 mg) and rocuronium bromide (50 mg). A com-
bination of propofol and morphine was administered
continually for sedation and analgesia. ‘Daily wake-up’
(approximately 30 min to 2 h) was performed accord-
ing to the routine protocol in our ICU. Our patient
underwent a percutaneous dilatational tracheostomy
three days later. Ten days after the tracheostomy, sedationis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the mechanical ventilator.
Our patient had severe, flaccid quadriplegia after his
tracheostomy. A neurologic examination demonstrated
bilateral flaccid weakness in his lower and upper extrem-
ities, which were Grade I according to the Medical Re-
search Council (MRC). Generalized areflexia was present
in all of his extremities. However, his sensory examination
was unremarkable. A nerve conduction study demon-
strated low-amplitude compound muscle action potentials
(CMAPs) with increased durations in the bilateral median,
ulnar, tibial and peroneal motor nerves. Results from
sensory nerve action potential and repetitive nerve
stimulation studies were normal. Needle electromyog-
raphy revealed positive sharp waves and myogenic
motor unit potentials in his biceps, deltoids and vastus
medialis (bilaterally). A muscle biopsy from the right
rectus femoris revealed extensive muscle fiber necrosis
via hematoxylin and eosin staining. No obvious inflam-
matory infiltration was detected (Figure 1A). ATPase
9.4 staining was reduced or absent in the type 2 fibers
(Figure 1B). Modified Gomori trichrome staining re-
vealed disarrayed muscle fibers without any ragged red
fibers (Figure 1C). No heavy lipid deposition was found
in the muscle fibers via Oil red O staining (Figure 1D).
Electron microscopy revealed prominent myofibrillar
disarray and uniform-sized mitochondria (Figure 2).Figure 1 Light microscopy of the rectus femoris muscle. (A) Hematoxy
prominent myofibrillar disarray. (B) ATPase (pH 9.4) reactions also revealed
(C) Modified Gomori trichrome staining revealed disarrayed muscle fibers w
lipid deposition in the muscle fibers.The serum level of creatine kinase was 180 U/L (range:
52 to 336 U/L).
Our patient was diagnosed with CIP/CIM. Adequate
enteral nutritional support, B vitamins and coenzyme
Q10 were administered immediately. Daily rehabilitation
was also performed under the guidance of an occupational
therapist. Methylprednisolone was reduced to 12 mg with-
out additional immunosuppressant therapy. Two weeks
later, the muscle strength in our patient’s extremities
began to improve slowly and reached MRC Grade III after
four weeks. A renal transplant biopsy revealed no evidence
of acute rejection. His muscle strength improved steadily,
and his activities of daily life were normal a year after he
was discharged.
Discussion
CIP/CIM, neuromuscular disorders that develop after
admission to the ICU, are associated with prolonged
mechanical ventilation and length of ICU stay, and in-
creased hospital mortality [5]. The clinical risk factors for
CIP/CIM include malnutrition, sepsis, a long duration of
mechanical ventilation, immobility, hyperglycemia, and
the use of glucocorticoids and neuromuscular blocking
agents [6-9]. In the reported case, although our patient
received only 50 mg of rocuronium bromide as rapid
sequence induction, its side effects could not be excluded
[10]. In addition, glucocorticoids given in combinationlin and eosin staining revealed extensive muscle fiber necrosis with
muscle fiber necrosis and decreased ATPase activity in type 2 fibers.
ithout any ragged red fibers. (D) Oil red O staining revealed no heavy
Figure 2 Electron micrograph of the rectus femoris muscle. (A) There were few thick myofilaments in the loose muscle, whereas Z discs
were less affected. (B) Mitochondria with abnormal appearance, such as disorganization and reduction or disappearance of the cristae.
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neuromuscular weakness. Previous studies have suggested
a high incidence of weakness in patients mechanically
ventilated for more than four to seven days. As a result,
13 days of mechanical ventilation was also considered to
be a risk factor of CIP/CIM in our patient.
The majority of CIP/CIM cases are diagnosed based
on clinical manifestation and electromyography. The
clinical characteristic of CIP/CIM is primary axonal
degeneration (without demyelination), which typically af-
fects motor nerves more than sensory nerves and results
in symmetrical muscular atrophy [11]. The electro-
physiological characteristics of these syndromes are re-
duced amplitudes and increased durations of CMAPs. In
CIP, the amplitudes of the sensory nerve action poten-
tials are also reduced [6]. Despite the invasive nature of
histopathological and immunopathological approaches,
they are considered to be the gold standard for diagnos-
ing CIP/CIM [12]. The pathological features of CIM are
classified into the following three main types: necrotiz-
ing, non-necrotizing, and selective loss of thick myosin
myofilaments [13]. Some studies have reported a signifi-
cant overlap between these pathophysiological processes
in critically ill patients [14]. The typical manifestations
of the patient reported in this paper were muscle weak-
ness, areflexia, myogenic damage observed via nerve
conduction and electromyographic study, and extensive
necrotizing myopathy observed via muscle biopsy. To
the best of our knowledge, this paper is the first reportof CIM with necrotizing myopathy in a renal transplant
recipient following severe pneumonia.
The main differential diagnosis in our patient was
steroid myopathy, which presented with a normal serum
cytokeratin level and muscular atrophy mainly involving
the proximal part of his lower limb. Unfortunately, we
selected the rectus femoris of our patient as the site for
an open muscle biopsy because of the severe muscular
atrophy in the proximal and distal parts of all four
extremities. Although the myogenic changes in the
needle electromyography and the type 2 fiber atrophy
found in steroid myopathy are similar to those in CIM,
such changes usually occur after several weeks or
months after steroid administration. Our patient had a
more rapid onset than those reported in steroid myop-
athy [15].
The management of our patient principally followed
the interdisciplinary approach for renal transplant
recipients with severe pneumonia in our ICU, although
lacking the support of randomized controlled trials [4].
Rehabilitation after CIP/CIM is incomplete and often
frustratingly slow, and many patients develop complica-
tions in an agonal state [11]. No specific therapy is
available, but preventive and supportive measures can be
beneficial in managing CIP/CIM. Early and aggressive
treatment of the underlying disease is the fundamental
strategy to prevent and treat CIP/CIM. Supportive mea-
sures include aggressive treatment of sepsis, reduction of
the dosage and duration of neuromuscular blocking
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teral feeding, and anti-oxidant therapy [16]. Studies have
suggested that physical therapy may help prevent CIP/
CIM or reduce their severity. Although no definitive rec-
ommendations regarding physical therapy for CIP/CIM
exist, an intensive physical therapy protocol might facilitate
the recovery process in patients with CIP/CIM [17-19].
In our case, the patient experienced acute quadriplegia
and subsequent rapid resolution after the aforementioned
management strategies were used.
Conclusion
CIP/CIM are complex syndromes that develop in critically
ill patients. These syndromes should be diagnosed at an
early stage. Treating the underlying disease, controlling
the risk factors and initiating long-term rehabilitation
might be beneficial to these patients.
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